Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05337631 · ClinicalTrials.gov registry record
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
A clinical trial of Oropharynx Cancer and HNSCC, sponsored by University Hospital Freiburg.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 18
- Study locations
NCT05337631: Recruiting study of Oropharynx Cancer and HNSCC, sponsored by University Hospital Freiburg.
NCT05337631 is a study of Oropharynx Cancer and HNSCC that is actively recruiting participants, run by University Hospital Freiburg. The registered enrollment target is 1,500 participants, above the 74-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target (1927% higher). The trial reports 18 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05337631, a study of Oropharynx Cancer and HNSCC, is actively recruiting participants, sponsored by University Hospital Freiburg.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 18
- Study locations
Study Summary
The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HNSCC patients based on the MACH-NC meta-analysis, it remains unknown whether state-of-the art radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), modern supportive treatments and alternative chemotherapy fractionation (e.g., cisplatin weekly) may have altered this observation. The objective of this retrospective multinational multicenter study is to determine the oncological outcomes of elderly patients (≥65 years) with locally advanced HNSCCs undergoing definitive (chemo-)radiation and to investigate the influence of concomitant chemotherapy on overall survival and progression-free survival after adjusting for potential confounder variables such as age, performance status and comorbidity burden.
Primary Outcome
Time from radiotherapy start until death from any cause
Conditions Studied
Study Locations (18)
Other
- Radiation Oncology Department, German Oncology Center - Limassol
- Brno University Hospital - Brno
- Department of Radiooncology and Radiotherapy, Charité-Universitätsmedizin Berlin - Berlin
- Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg - Erlangen
- Department of Radiotherapy and Oncology, Goethe-University Frankfurt am Main - Frankfurt
- University of Giessen - Giessen
- Martin-Luther-Universität Halle-Wittenberg - Halle
- Jena University Hospital - Jena
- Department of Radiation Oncology, University Hospital Schleswig-Holstein - Kiel
- Department of Radiation Oncology, University Medical Center Leipzig - Leipzig
- Department of Radiation Oncology, University Medical Center Mainz - Mainz
- Department of Radiation Oncology, University Hospital, LMU Munich - Munich
- Department of Radiation Oncology, University Hospital Würzburg - Würzburg
- Department of Radiation Oncology, University Hospital Zurich (USZ), University of Zurich (UZH) - Zurich
Ohio
- Department of Radiation Oncology, Case Western Reserve University - Cleveland
- Division of Radiation Oncology, The Ohio State University Wexner - Columbus
Maryland
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine - Baltimore
New York
- Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2026-12-31 |
What NCT05337631 shows while recruiting
NCT05337631 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, above the 74-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target (1927% higher).
The record links to 5 conditions, with Oropharynx Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT05337631 lists 18 locations in 4 states (Other, Ohio, Maryland).
Frequently Asked Questions
What is clinical trial NCT05337631 about?
NCT05337631 is a clinical study titled "Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy". The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HNS...
What is the current status of trial NCT05337631?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2021-06-01. Estimated completion is 2026-12-31.
What conditions does trial NCT05337631 study?
This clinical trial studies the following conditions: Oropharynx Cancer, HNSCC, Oral Cavity Cancer, Larynx Cancer, Hypopharynx Cancer.
Who is sponsoring clinical trial NCT05337631?
This trial is sponsored by University Hospital Freiburg, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05337631 being conducted?
This trial has 18 study locations across Maryland, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharynx Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05337631's enrollment target sits among peer trials
1,500 1st of 26 higher than 26 of 26 other Oropharynx Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Oropharynx Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
RECRUITING · Phase 2
-
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
RECRUITING · Phase 2
-
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI